Title : MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.

Pub. Date : 2010 Aug

PMID : 20689757






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We hypothesized that assessing the gene expression of the chemotherapy response modifiers multidrug resistance gene 1 (MDR1) and excision repair cross-complementing 1 (ERCC1) may help identify the group of patients benefiting from cisplatin-based adjuvant chemotherapy. Cisplatin ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens
2 We hypothesized that assessing the gene expression of the chemotherapy response modifiers multidrug resistance gene 1 (MDR1) and excision repair cross-complementing 1 (ERCC1) may help identify the group of patients benefiting from cisplatin-based adjuvant chemotherapy. Cisplatin ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens
3 CONCLUSIONS: High MDR1 and ERCC1 gene expressions are associated with inferior outcome after cisplatin-based adjuvant chemotherapy for locally advanced bladder cancer. Cisplatin ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens